Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies

[1] Pal T(2005)BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 2807-16

[2] Permuth-Wey J(2021)Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Lancet 397 2182-93

[3] Betts JA(2015)Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy Cancer Res 75 4669-74

[4] Krischer JP(2001)Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13–evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo Cancer Biother Radiopharm 16 187-203

[5] Fiorica J(1998)Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated Tumor killing in patients treated with Ovarex mAb B43.13 (Ab1) Cancer Immunol Immunother 46 201-12

[6] Arango H(2003)Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent Ovarian cancer Am J Obstet Gynecol 189 28-36

[7] Menon U(2009)The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced Ovarian cancer J Immunother 32 54-65

[8] Gentry-Maharaj A(2009)Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced Ovarian cancer J Clin Oncol 27 418-25

[9] Burnell M(2007)Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer Clin Cancer Res 13 4026-61

[10] Singh N(2013)Abagovomab as maintenance therapy in patients with epithelial Ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study J Clin Oncol 31 1554-45

[1] Pal T(2005)BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 2807-16

[2] Permuth-Wey J(2021)Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Lancet 397 2182-93

[3] Betts JA(2015)Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy Cancer Res 75 4669-74

[4] Krischer JP(2001)Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13–evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo Cancer Biother Radiopharm 16 187-203

[5] Fiorica J(1998)Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated Tumor killing in patients treated with Ovarex mAb B43.13 (Ab1) Cancer Immunol Immunother 46 201-12

[6] Arango H(2003)Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent Ovarian cancer Am J Obstet Gynecol 189 28-36

[7] Menon U(2009)The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced Ovarian cancer J Immunother 32 54-65

[8] Gentry-Maharaj A(2009)Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced Ovarian cancer J Clin Oncol 27 418-25

[9] Burnell M(2007)Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer Clin Cancer Res 13 4026-61

[10] Singh N(2013)Abagovomab as maintenance therapy in patients with epithelial Ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study J Clin Oncol 31 1554-45